siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth

Duggan, S.P., Garry, C., Behan, F.M., Phipps, S., Kudo, H., Kirca, M., Zaheer, A., McGarrigle, S., Reynolds, J.V., Goldin, R., Kalloger, S.E., Schaeffer, D.F., Long, A., Strid, J. & Kelleher, D., siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth, Cellular and Molecular Gastroenterology and Hepatology, 5, 4, 2018, 569-590

Abstract

This study de fi nes immune-associated factors supportive of esophageal adenocarcinoma cell growth through small interfering RNA screening and pathologic and functional studies. Fostamatinib R788, targeting Janus kinase/signal transducer-and-activator of transcription and TYRO protein tyrosine kinase binding protein/spleen tyrosine kinase/AKT serine-threonine kinase pathways, induced esophageal adenocarcinoma cell death and reduced tumor burden in xenografted mice.